Format

Send to

Choose Destination
See comment in PubMed Commons below
Biomed Pharmacother. 2009 Nov;63(9):672-8. doi: 10.1016/j.biopha.2009.02.002. Epub 2009 Feb 28.

Urinary TGF-beta1 as an indicator of antiproteinuric response to angiotensin II receptor blocker in proteinuric renal diseases.

Author information

1
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. amp97@yumc.yonsei.ac.kr

Abstract

BACKGROUND:

Angiotensin II receptor blockers (ARBs) reduce proteinuria, however, with large inter-individual variability. The present study investigated whether urinary transforming growth factor-beta1 (TGF-beta1) might predict the antiproteinuric efficacy of ARB in non-diabetic chronic renal disease.

METHODS:

Non-diabetic patients with proteinuria (>1 g/day) received 50 mg of losartan daily followed by 100 mg in two treatment periods, each lasting 12 weeks. Clinical parameters and urinary TGF-beta1 levels were measured at baseline and during the treatment period.

RESULTS:

In the whole group of patients, losartan treatment effectively decreased proteinuria. However, considerable differences existed among individual antiproteinuric responses. Good (n=34) or low (n=15) responders showed average proteinuria reduction of 69% or 17% from baseline, respectively. Both groups showed similar baseline biochemical and renal parameters and comparable degree of mean arterial blood pressure (MAP) reduction. However, the low responders were older and showed significantly higher baseline urinary TGF-beta1 levels. On multiple regression analysis, age, baseline urinary TGF-beta1 and % reduction in urinary TGF-beta1 and % reduction in MAP significantly predicted antiproteinuric response to losartan therapy.

CONCLUSION:

The present data suggest that the determination of baseline urinary TGF-beta1 could be an useful indicator of short-term antiproteinuric response to ARB treatment in non-diabetic nephropathy.

PMID:
19278811
DOI:
10.1016/j.biopha.2009.02.002
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center